Artia Global Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Artia Global Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-55,100	Closed	-$21.6M	–	73
2025 Q3	$21.6M	Buy	55,100 +50,700	+1,152%	+$21.2M	3.42%	10
2025 Q2	$1.96M	Buy	+4,400	New	+$2.03M	0.47%	25
2024 Q4	–	Sell	-18,900	Closed	-$8.79M	–	56
2024 Q3	$8.79M	Hold	18,900	–	–	2.4%	9
2024 Q2	$8.86M	Sell	18,900 -10,000	-35%	-$4.34M	1.71%	9
2024 Q1	$12.1M	Buy	+28,900	New	+$12.2M	2.43%	10
2023 Q4	–	Sell	-18,314	Closed	-$6.37M	–	37
2023 Q3	$6.37M	Hold	18,314	–	–	2.65%	12
2023 Q2	$6.44M	Buy	18,314 +11,200	+157%	+$3.77M	2.22%	17
2023 Q1	$2.24M	Hold	7,114	–	–	0.83%	22
2022 Q4	$2.05M	Buy	+7,114	New	+$2.17M	0.78%	19

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Artia Global Partners's VRTX Position: Q4 2025 in Review

Artia Global Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 55,100 shares — an estimated $21.6M sold.

Artia Global Partners first reported a position in VRTX in Q4 2022 and held it in 9 quarters. The position peaked at $21.6M in Q3 2025. 1,668 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Artia Global Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Artia Global Partners sold 55,100 Vertex Pharmaceuticals shares in Q4 2025, an estimated $21.6M.
Artia Global Partners first reported a position in Vertex Pharmaceuticals in Q4 2022 and held it in 9 quarters.
Artia Global Partners's Vertex Pharmaceuticals position peaked at $21.6M in Q3 2025.
1,668 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Artia Global Partners's 13F filing for Q4 2025, filed 17 Feb 2026.